1
|
How stress management improves quality of life after treatment for breast cancer.
|
J Consult Clin Psychol
|
2006
|
1.81
|
2
|
Stress management intervention reduces serum cortisol and increases relaxation during treatment for nonmetastatic breast cancer.
|
Psychosom Med
|
2008
|
1.27
|
3
|
Treating breast cancer in the 21st century: emerging biological therapies.
|
J Cancer
|
2013
|
1.26
|
4
|
Molecular profiling for breast cancer: a comprehensive review.
|
Biomark Cancer
|
2013
|
1.23
|
5
|
Molecularly targeted therapies for metastatic triple-negative breast cancer.
|
Breast Cancer Res Treat
|
2013
|
1.21
|
6
|
Bevacizumab in the treatment of metastatic breast cancer: friend or foe?
|
Curr Oncol Rep
|
2012
|
1.17
|
7
|
A woman's heart: the impact of adjuvant endocrine therapy on cardiovascular health.
|
Cancer
|
2009
|
1.14
|
8
|
Phase II study of palifermin and concurrent chemoradiation in head and neck squamous cell carcinoma.
|
J Clin Oncol
|
2008
|
1.14
|
9
|
Final results of a phase II study of nab-paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer.
|
Breast Cancer Res Treat
|
2010
|
1.14
|
10
|
Participation in cancer clinical trials: why are patients not participating?
|
Med Decis Making
|
2013
|
1.10
|
11
|
Phase 2 study of eribulin mesylate as first-line therapy for locally recurrent or metastatic human epidermal growth factor receptor 2-negative breast cancer.
|
Breast Cancer Res Treat
|
2014
|
1.05
|
12
|
Acceleration of telomere loss by chemotherapy is greater in older patients with locally advanced head and neck cancer.
|
Clin Cancer Res
|
2006
|
1.02
|
13
|
Primary ectopic breast cancer presenting as a vulvar mass.
|
Clin Breast Cancer
|
2006
|
1.01
|
14
|
Racial differences in acute toxicities of neoadjuvant or adjuvant chemotherapy in patients with early-stage breast cancer.
|
Eur J Cancer
|
2011
|
0.95
|
15
|
Systemic therapy options in BRCA mutation-associated breast cancer.
|
Breast Cancer Res Treat
|
2012
|
0.95
|
16
|
Nab-paclitaxel in the treatment of metastatic breast cancer: a comprehensive review.
|
Expert Rev Clin Pharmacol
|
2011
|
0.90
|
17
|
A cost-benefit analysis of bevacizumab in combination with paclitaxel in the first-line treatment of patients with metastatic breast cancer.
|
Breast Cancer Res Treat
|
2011
|
0.90
|
18
|
Sleep quality and fatigue after a stress management intervention for women with early-stage breast cancer in southern Florida.
|
Int J Behav Med
|
2014
|
0.89
|
19
|
Molecular subtyping predicts pathologic tumor response in early-stage breast cancer treated with neoadjuvant docetaxel plus capecitabine with or without trastuzumab chemotherapy.
|
Med Oncol
|
2014
|
0.86
|
20
|
Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.
|
Cancer Treat Rev
|
2011
|
0.86
|
21
|
Concurrent celecoxib with 5-fluorouracil/epirubicin/cyclophosphamide followed by docetaxel for stages II - III invasive breast cancer: the OOTR-N001 study.
|
Expert Opin Investig Drugs
|
2013
|
0.85
|
22
|
Gemcitabine and taxanes in metastatic breast cancer: a systematic review.
|
Ther Clin Risk Manag
|
2008
|
0.85
|
23
|
A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer.
|
Breast Cancer Res Treat
|
2012
|
0.84
|
24
|
Chemoprevention of breast cancer.
|
Expert Rev Anticancer Ther
|
2008
|
0.84
|
25
|
Exemestane in the adjuvant treatment of breast cancer in postmenopausal women.
|
Breast Cancer (Auckl)
|
2011
|
0.83
|
26
|
Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer.
|
J Support Oncol
|
2010
|
0.83
|
27
|
Can we replace the microscope with microarrays for diagnosis, prognosis and treatment of early breast cancer?
|
Expert Opin Ther Targets
|
2012
|
0.83
|
28
|
Long-Term Complete Remission with nab-Paclitaxel, Bevacizumab, and Gemcitabine Combination Therapy in a Patient with Triple-Negative Metastatic Breast Cancer.
|
Case Rep Oncol
|
2012
|
0.83
|
29
|
Comparison of CD34 and monocyte-derived dendritic cells from mobilized peripheral blood from cancer patients.
|
Stem Cells
|
2005
|
0.82
|
30
|
Can mammographic and sonographic imaging features predict the Oncotype DX™ recurrence score in T1 and T2, hormone receptor positive, HER2 negative and axillary lymph node negative breast cancers?
|
Breast Cancer Res Treat
|
2014
|
0.81
|
31
|
Is the Improved Efficacy of Trastuzumab and Lapatinib Combination Worth the Added Toxicity? A Discussion of Current Evidence, Recommendations, and Ethical Issues Regarding Dual HER2-Targeted Therapy.
|
Breast Cancer (Auckl)
|
2012
|
0.79
|
32
|
Association of age and overall survival in capecitabine-treated patients with metastatic breast cancer in clinical trials.
|
Breast Cancer Res Treat
|
2010
|
0.79
|
33
|
Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review.
|
J Med Case Rep
|
2012
|
0.78
|
34
|
Postsurgical Depressive Symptoms and Proinflammatory Cytokine Elevations in Women Undergoing Primary Treatment for Breast Cancer.
|
Psychosom Med
|
2016
|
0.78
|
35
|
Gene expression profiling in breast cancer.
|
Am J Transl Res
|
2013
|
0.77
|
36
|
Influence of mesna on the pharmacokinetics of cisplatin and carboplatin in pediatric cancer patients.
|
Med Oncol
|
2004
|
0.77
|
37
|
Macrophages as independent prognostic factors in small T1 breast cancers.
|
Oncol Rep
|
2012
|
0.77
|
38
|
Introduction to special issue translational goals of neoadjuvant therapy.
|
Breast Cancer Res Treat
|
2012
|
0.75
|
39
|
Adjuvant therapy for HER2 positive breast cancer: are anthracyclines still necessary?
|
Clin Adv Hematol Oncol
|
2008
|
0.75
|
40
|
Priming with dendritic cells can generate strong cytotoxic T cell responses to chronic myelogenous leukemia cells in vitro.
|
Stem Cells Dev
|
2004
|
0.75
|
41
|
Biologic impact and clinical implication of mTOR inhibition in metastatic breast cancer.
|
Int J Biol Markers
|
2013
|
0.75
|